Tag Archive for: Daiichi Sankyo

AstraZeneca and Daiichi Sankyo on Monday revealed additional data from the Phase III TROPION-Lung01 study, showing that their investigational antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) failed to significantly improve overall survival in non-small cell lung cancer patients.

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast patients with low and ultralow HER2 expression levels who had received at least one line of systemic treatment.

The FDA on Friday approved AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2-positive solid tumors in adults who have undergone prior systemic treatment and have no alternative treatment options.

With the investment in the plant, Daiichi Sankyo is looking to create new laboratories for its antibody drug conjugates used to develop and manufacture therapies for breast, lung and stomach cancers.

The Japanese pharma now expects the AstraZeneca-partnered Enhertu to bring in approximately $2.61 billion for the fiscal year 2023, this time driven by growth outside the United States.

BioNTech and its partner Duality Biologics said they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca, and Daiichi Sankyo.

In its final decision, the U.S. PTO invalidated all of the claims in Seagen’s patent 10,808,039, which covers the use of auristatin peptides connected to antibody-drug conjugates (ADCs) via a specific linker technology.

The mRNA-based shot was initially approved as a booster in August, becoming Japan’s first home-grown shot for the coronavirus.

Malaysia’s IHH Healthcare said its unit filed a claim against Japan’s Daiichi Sankyo in mid-October seeking damages in excess of 20 billion yen ($131.86 million) in relation to its stake buy in India’s Fortis Healthcare.

The companies presented data from two pivotal studies of Dato-DXd, focusing on safety concerns and survival data for the investigational antibody-drug conjugate candidate in lung and breast cancer.